Kite Pharma Inc. recently told investors that it's on the cusp of producing late-stage data that could enable a filing of its lead cancer immunotherapy candidate, KTE-C19, but the biotech also recently made a move toward producing off-the-shelf T-cell cancer therapies under a technology licensing deal with University of California, Los Angeles.
On July 25, Kite licensed exclusive global rights to allogeneic T-cell technology intellectual property from UCLA that could enable it...







